Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.47 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482223 | 1.00 | BRD4 (0.47) | BRD4TAF1CECR2BRD9HTT | |
| SCHEMBL19657112 | 0.85 | HTT (0.47) | BRD4TAF1CECR2BRD9HTT | |
| SCHEMBL19651856 | 0.81 | HSP90AB1 (0.46) | BRD4TAF1CECR2BRD9HTT | |
| SCHEMBL19657110 | 0.74 | ACACB (0.53) | BRD4TAF1CECR2BRD9HPGD | |
| SCHEMBL5156191 | 0.74 | DHODH (0.47) | HTTHPGDSMN1; SMN2MAPTKDM4E | |
| SCHEMBL23123464 | 0.74 | CCR5 (0.43) | HTTHPGDSMN1; SMN2RAB9AMAPT | |
| SCHEMBL13373365 | 0.72 | HTT (0.47) | HTTHPGDSMN1; SMN2MAPTKDM4E | |
| SCHEMBL19651857 | 0.72 | HSP90AB1 (0.54) | BRD4TAF1CECR2BRD9SMN1; SMN2 | |
| SCHEMBL30029436 | 0.71 | PIK3C2B (0.44) | — | |
| SCHEMBL17292508 | 0.71 | PIK3C2B (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | BRD4 1/4885TAF1 437/4885CECR2 246/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | BRD4 1/4885TAF1 437/4885CECR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.